S015 The 2027 Debates: Controversies in Dermatology
DESCRIPTION
Evidence-based medicine is the conscientious and judicious use of the strongest current data in making decisions on how we care for our patients. Advances in technology, development of new therapies, and acquisition of new data challenge our best practices and may at the same time stimulate controversy. This session is designed for interactive discussion and critical thinking regarding some of the emerging issues that we are actively encountering in this current day.
LEARNING OBJECTIVES
Critically evaluate key issues and challenges in deploying molecular testing for the determination of melanoma risk and outcomes.
Define and recognize the current opportunities and challenges with developing and using Artificial Intelligence applications in dermatology.
Critically evaluate the key issues and challenges associated with melanoma (over)diagnosis and skin cancer screening.
SCHEDULE
1:00 PM
Discussion
1:00 PM
Discussion
Kenneth Y. Tsai, MD, PhD, FAAD, Emily Y. Chu, MD, PhD, FAAD, Sairekha Ravichandran, MD, FAAD, Yevgeniy Semenov, MD, MS, FAAD, Shannon Wongvibulsin, MD, PhD, FAAD
DIRECTOR
Kenneth Y. Tsai, MD, PhD, FAAD
H. Lee Moffitt Cancer Center & Research Institute
SPEAKERS
Emily Y. Chu, MD, PhD, FAAD
University of Pennsylvania
Sairekha Ravichandran, MD, FAAD
Assistnat Professor, University of South Florida, Department of Dermatology & Cutaneous Surgery
Yevgeniy Semenov, MD, MS, FAAD
Shannon Wongvibulsin, MD, PhD, FAAD
University of California, Irvine
DISCLOSURES
Emily Y. Chu, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Sairekha Ravichandran, MD, FAAD
Dermatology Times (MMM MultiMedia Medical, LLC) – Advisory Board(Honoraria);
Yevgeniy Semenov, MD, MS, FAAD
Alterome Therapeutics – Consultant (1099 relationship)(Honoraria); Arcutis Biotherapeutics – Consultant (1099 relationship)(Honoraria); Bristol Myers Squibb – Consultant (1099 relationship)(Honoraria); Galderma – Advisory Board(Honoraria); Journal of the American Academy of Dermatology – Other(Salary); Pfizer Inc. – Consultant (1099 relationship)(Honoraria); Pyxis Oncology – Consultant (1099 relationship)(Honoraria); Regeneron – Advisory Board(Honoraria); Sanofi – Advisory Board(Honoraria);
Kenneth Y. Tsai, MD, PhD, FAAD
3CC - Third Culture Capital – Stockholder(No Compensation Received); Altos Labs – Consultant (1099 relationship)(Fees); Ankyra Therapeutics – Independent Contractor(Grants/Research Funding); APIS Assay Technologies – Independent Contractor(Grants/Research Funding); DX Biosciences, Inc – Consultant(Stock Options); Incyte Corporation – Investigator(Grants/Research Funding); NFlection Therapeutics, Inc – Consultant(Fees); Regeneron Pharmaceuticals Inc – Advisory Board(Fees); UpToDate – Independent Contractor(Fees); Verrica Pharmaceuticals Inc – Independent Contractor(Fees);
Shannon Wongvibulsin, MD, PhD, FAAD
Anatomy Mapper – Consultant (1099 relationship)(Fees); Beiersdorf – Consultant (1099 relationship)(Fees); Insight Venture Management – Consultant (1099 relationship)(Fees); VisualDx – Consultant (1099 relationship)(Honoraria);